Arizona Tribune - Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026

TD Cowen 46th Annual Health Care Conference; Boston, MA - March 2-4, 2026
Format: Fireside Chat
Day/Time: Tuesday, March 3 at 11:50 A.M. ET
Webcast: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/6QuKhqDYvNSrPH8co9v5gd

Leerink Global Healthcare Conference; Miami, FL - March 8-11, 2026
Format: Fireside Chat
Day/Time: Monday, March 9 at 4:20 P.M. ET
Webcast: https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/K8FdPptAY5cyfndeY9RPP9

Jefferies Biotech on the Beach Summit; Miami, FL - March 10-11, 2026
Format: One-on-one Meetings
Day/Time: Tuesday, March 10

Citizens Life Sciences Conference; Miami, FL - March 10-11, 2026
Format: Fireside Chat
Day/Time: Wednesday, March 11 at 1:05 P.M. ET
Webcast: https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/UWj58vHDxUk6PseGJr4ebs

Barclays 28th Annual Global Healthcare Conference; Miami, FL - March 10-12, 2026
Format: Fireside Chat
Day/Time: Thursday, March 12 at 11:30 A.M. ET
Webcast: https://cc.webcasts.com/barc002/031026a_js/?entity=30_ESKWJT8

If you are interested in meeting with the Protagonist team during the conferences, please reach out to your respective conference representative.

A replay of the presentations will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.

About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with a New Drug Application (NDA) for icotrokinra submitted to the FDA in July, and an NDA for rusfertide submitted in December 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R"), which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.

More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.

Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
[email protected]

Media Contact
Virginia Amann
ENTENTE Network of Companies
[email protected]

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

W.Stewart--AT